Annexon, Inc. 8-K

What Happened Annexon, Inc. (ANNX) filed an Item 8.01 8-K on January 12, 2026, issuing a press release titled “Annexon Accelerating Next Generation Targeted Immunotherapy Platform for Treatment of Neuroinflammatory Diseases with Multiple Registrational Milestones in 2026.” The company announced its 2026 strategic priorities and said its lead targeted immunotherapy programs have multiple registrational milestones expected in 2026. A copy of the press release is furnished as Exhibit 99.1 to the filing.

Key Details

• Filing date: January 12, 2026 (Item 8.01 — Other Events).
• Press release title: “Annexon Accelerating Next Generation Targeted Immunotherapy Platform for Treatment of Neuroinflammatory Diseases with Multiple Registrational Milestones in 2026.”
• Corporate focus: accelerating a next‑generation targeted immunotherapy platform for neuroinflammatory diseases.
• Disclosure: the press release outlining 2026 priorities and milestones is attached as Exhibit 99.1.

Why It Matters This 8-K signals that Annexon expects several registrational milestones in 2026 for its lead programs, which can be important development and regulatory inflection points for a clinical‑stage biotech. Investors should review the attached press release for program‑level timing and specifics (clinical readouts, filings, or other milestones) because those events can materially affect the company’s development outlook and valuation.